BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key CatalystSeeking Alpha • 11/04/26
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/04/26
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?Zacks Investment Research • 10/30/26
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific MeetingGlobeNewsWire • 10/29/26
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/28/26
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAEGlobeNewsWire • 10/21/26
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and GrowthGlobeNewsWire • 10/05/26
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 08/31/26
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a BetZacks Investment Research • 08/28/26